FLT3 and acute myeloid leukemia: On the other hand, use of a DNA‐PKcs inhibitor such as M3814 was shown to enhance DNA damage signaling, synergize the effects of topoisomerase II inhibitors and sensitize AML cells to P53‐dependent apoptosis, regardless of FLT3 mutational status, the surrounding cellular context, and its combination with cytarabine.73